A 12-YEAR-OLD BOY WITH MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUCCESSFULLY TREATED WITH HAART INCLUDING RITONAVIR-BOOSTED TIPRANAVIR ORAL SOLUTION AND ENFUVIRTIDE

被引：0

作者：

Feiterna-Sperling, C. ^{[1
]}

Walter, H. ^{[2
]}

Wahn, V. ^{[1
]}

Kleinkauf, N. ^{[3
]}

机构：

[1] Univ Med Berlin, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany

[2] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Erlangen, Germany

[3] Univ Med Berlin, Charite, Inst Virol, D-13353 Berlin, Germany

来源：

EUROPEAN JOURNAL OF MEDICAL RESEARCH | 2009年 / 14卷 / 01期

关键词：

HIV-1; infection; multidrug-resistant HIV-1 highly active antiretroviral therapy; tipranavir oral solution; enfuvirtide; ACTIVE ANTIRETROVIRAL THERAPY; EFFICACY; CHILDREN; REGIMEN; COMBINATION; ADOLESCENTS; SAFETY; INFECTION; ADHERENCE; MORTALITY;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

For intensively pretreated pediatric patients with human immunodeficiency virus type 1 (HIV-1) infection, the treatment options available are limited. We report the case of a highly treatment-experienced 12-year-old boy with multidrug-resistant HIV-1, who was successfully treated with highly active antiretroviral therapy (HAART) including ritonavir-boosted tipranavir oral solution, a novel non-peptic protease inhibitor, and enfuvirtide.

引用

页码：44 / 46

页数：3

共 14 条

[1] [Anonymous], 2008, DEP HLTH HUMAN SERVI, P1
[2] [Anonymous], GUID US ANT AG PED H
[3] *BOEHR ING INT GMB, 2007, APT TIPR CAPS SUMM P
[4] Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Clotet, Bonaventura
Bellos, Nicholas
Molina, Jean-Michel
Cooper, David
Goffard, Jean-Chrostophe
Lazzarin, Adriano
Woehrmann, Andrej
Katlama, Christine
Wilkin, Timothy
Haubrich, Richard
Cohen, Calvin
Farthing, Charles
Jayaweera, Dushyantha
Markowitz, Martin
Ruane, Peter
Spinosa-Guzman, Sabrina
Lefebvre, Eric
[J]. LANCET, 2007, 369 (9568) : 1169 - 1178
[5] Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
Cozzi-Lepri, Alessandro
Phillips, Andrew N.
Ruiz, Lidia
Clotet, Bonaventura
Loveday, Clive
Kjaer, Jesper
Mens, Helene
Clumeck, Nathan
Viksna, Ludmila
Antunes, Francisco
Machala, Ladislav
Lundgren, Jens D.
[J]. AIDS, 2007, 21 (06) : 721 - 732
[6] Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1
Gortmaker, SL
Hughes, M
Cervia, J
Brady, M
Johnson, GM
Seage, GR
Song, LY
Dankner, WM
Oleske, JM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (21) : 1522 - 1528
[7] Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Hicks, Charles B.
Cahn, Pedro
Cooper, David A.
Walmsley, Sharon L.
Katlama, Christine
Clotet, Bonaventura
Lazzarin, Adriano
Johnson, Margaret A.
Neubacher, Dietmar
Mayers, Douglas
Valdez, Hernan
[J]. LANCET, 2006, 368 (9534) : 466 - 475
[8] Patient, Caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents
Martin, Staci
Elliott-DeSorbo, Deborah K.
Wolters, Pamela L.
Toledo-Tamula, Mary Anne
Roby, Gregg
Zeichner, Steve
Wood, Lauren V.
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (01) : 61 - 67
[9] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
Palella, FJ
Delaney, KM
Moorman, AC
Loveless, MO
Fuhrer, J
Satten, GA
Aschman, DJ
Holmberg, SD
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 853 - 860
[10] SABO JP, 2006, 13 C RETR VIR OPP IN

← 1 2 →